Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Lacosamide (Vimpat) is indicated for the treatment of partial-onset seizures in patients 1 month of age and older, and as an adjunctive therapy in treating primary generalized tonic-clonic seizures in patients aged 4 years and above.
• Eleven studies were reviewed to gather information about Vimpat's efficacy, safety, tolerability, and comparison with other anti-seizure medications (ASMs).
• Lacosamide showed significant efficacy in lowering seizure frequency compared to placebo. It was particularly effective alongside Cenobamate (CNB) and Eslicarbazepine Acetate (ESL), which are also third-generation ASMs.
• Lacosamide demonstrated safety and effectiveness among special populations such as those suffering from Lennox-Gastaut syndrome, a difficult-to-manage condition. However, some reports noted worsening seizures among these patients.
• Compared to other ASMs like Brivaracetam (BRV), ESL, CNB, and Perampanel (PER), lacosamide and BRV had fewer participants experiencing treatment-emergent adverse events (TEAEs), indicating it may be better tolerated than some alternatives.
• For pediatric populations, lacosamide was deemed safe concerning movement disorders. The specific adverse events did not significantly differ from those observed in adult populations, indicating similar tolerance levels across different ages.
• Among adults with drug-resistant focal-onset seizures, lacosamide proved effective as an adjunctive therapy. It showed comparable rates of seizure control to phenytoin (PHT) but resulted in fewer serious adverse events, making it a safer alternative.
• Limited evidence suggests a potential role for lacosamide in the treatment of Lennox-Gastaut Syndrome (LGS). However, caution is advised due to the possibility of an increase in seizure frequency among this patient group.